2026-05-10T09:30:59Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/150922024-09-27T08:02:08Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Brandi, Paola author Conejero, Laura author Cueto, Francisco J author Martínez-Cano, Sarai author Dunphy, Gillian author Gómez, Manuel J author Relaño, Carlos author Saz-Leal, Paula author Enamorado, Michel author Quintas, Ana author Dopazo, Ana author Amores-Iniesta, Joaquin author Del Fresno, Carlos author Nistal-Villán, Estanislao author Ardavín, Carlos author Nieto, Antonio author Casanovas, Miguel author Subiza, José Luis author Sancho, David author 2022-01 MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung immune landscape and provides long-term heterologous protection against viral respiratory infections in mice. Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. Moreover, pharmacological inhibition of trained immunity with metformin abrogates the protection conferred by MV130 against influenza A virus respiratory infection. MV130 induces reprogramming of both mouse bone marrow progenitor cells and in vitro human monocytes, promoting an enhanced cytokine production that relies on a metabolic shift. Our results unveil that the mucosal administration of a fully inactivated bacterial vaccine provides protection against viral infections by a mechanism associated with the induction of trained immunity. Cell Rep . 2022 Jan 4;38(1):110184 10.1016/j.celrep.2021.110184 2211-1247 Cell reports 34986349 http://hdl.handle.net/20.500.12105/15092 Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.